Thermo Fisher Scientifics Advanced Granulation Technology Media Manufacturing Site Expands in Scotland
Essential products needed for the production of biotherapeutics and vaccines for diseases such as influenza and dengue fever will be produced in Scotland, following the launch of the new state-of-the-art facility near Glasgow.
Thermo Fisher Scientific has expanded its campus in Inchinnan, Scotland, with the addition of a cutting-edge facility that will manufacture a novel and proprietary dry media powder known as Gibco Advanced Granulation Technology (AGT). AGT products are animal-origin free, single-component, particulate-free powders for chemically defined cell culture. The AGT dry media format reduces the number of components necessary in cell culture manufacturing processes. Used to manufacture biologics, including vaccines, anti-cancer therapeutics and other life-saving drugs, AGT offers customers the benefits of traditional liquid media without the associated cost, storage, and transportation challenges.
The £14 million investment increases the assurance of supply for customers and complements another Thermo Fisher facility in Grand Island, New York, where AGT is also manufactured. The new facility will add to the Inchinnan site’s existing manufacturing operations, which produce liquid media for a range of research and production applications.
“This is a strategically important facility that will secure supplies for our target markets all over the world,” said Mark Smedley, President of Europe, Middle East and Africa, Life Sciences Solutions, for Thermo Fisher. “It’s important to choose the right location for a factory of this significance, and we felt the depth of experience, skills and expertise at Inchinnan made it the perfect place to make this investment.”
This investment is linked to on-going support from Scottish Enterprise to assist Thermo Fisher in expanding the company’s global manufacturing network.
"Congratulations to Thermo Fisher on the opening of their impressive new facility at Inchinnan,” said Paul Lewis, Managing Director, Scottish Development International and Scottish Enterprise International Operations. "Scotland is already home to a thriving life sciences cluster which is recognised worldwide as one of the most accessible, well-connected and collaborative in Europe. It is major investments like this that allow us to continue to attract ambitious, international companies such as Thermo Fisher to not only locate in Scotland but to strengthen their business base here and to invest in long-term growth."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance